Publications by authors named "David S Spriggs"

Claim this Profile
A
A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumors.
J Paul Monk, Miguel Villalona-Calero, Joe Larkin, Greg Otterson, David S Spriggs

Invest New Drugs· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis